A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma

被引：3
|
作者：
Wen, Patrick V.
Omuro, Antonio M.
Batchelor, Tracy T.
Lai, Albert
Mellinghoff, Ingo K.
Nghiemphu, Leia
Norden, Andrew
Gendreau, Steven B.
Laird, A. Douglas
Nguyen, Linh
Cloughesy, Timothy
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B265
引用
收藏
页数：3
相关论文
共 38 条
  • [1] A Phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.
    Nghiemphu, P. L.
    Omuro, A. M.
    Cloughesy, T.
    Mellinghoff, I. K.
    Norden, A. G.
    Nguyen, L. T.
    Rajangam, K.
    Wen, P. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors
    Janne, Pasi A.
    Felip, Enriqueta
    Cedres, Susana
    Cohen, Steven J.
    Engelman, Jeffrey A.
    Lucca, Joan
    Martinez, Pablo
    von Mehren, Margaret
    Gendreau, Steven B.
    Lara, Katherine K.
    Martini, Jean-Francois
    Cohen, Roger B.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid fumors.
    Cohen, R. B.
    Janne, P. A.
    Engelman, J. A.
    Martinez, P.
    Nishida, Y.
    Gendreau, S.
    Wu, B.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
    Brana, I.
    LoRusso, P.
    Baselga, J.
    Heath, E. I.
    Patnaik, A.
    Gendreau, S.
    Laird, A.
    Papadapoulos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
    LoRusso, P.
    Markman, B.
    Tabernero, J.
    Shazer, R.
    Nguyen, L.
    Heath, E.
    Patnaik, A.
    Papadopoulos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Jaenne, Pasi A.
    Cohen, Roger B.
    Laird, A. Douglas
    Mace, Sandrine
    Engelman, Jeffrey A.
    Ruiz-Soto, Rodrigo
    Rockich, Kevin
    Xu, Jianbo
    Shapiro, Geoffrey I.
    Martinez, Pablo
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 316 - 323
  • [7] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Tabernero, Josep
    Markman, Ben
    Patnaik, Amita
    Tolcher, Anthony W.
    Baselga, Jose
    Shi, Weiliang
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Laird, A. Douglas
    Miles, Dale
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2014, 20 (09) : 2445 - 2456
  • [8] Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
    Wen, Patrick Y.
    Omuro, Antonio
    Ahluwalia, Manmeet S.
    Fathallah-Shaykh, Hassan M.
    Mohile, Nimish
    Lager, Joanne J.
    Laird, A. Douglas
    Tang, Jiali
    Jiang, Jason
    Egile, Coumaran
    Cloughesy, Timothy F.
    NEURO-ONCOLOGY, 2015, 17 (09) : 1275 - 1283
  • [9] Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
    Papadopoulos, Kyriakos P.
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Jiang, Jason
    Shi, Weiliang
    Bentzien, Frauke
    Rasco, Drew
    Abrisqueta, Pau
    Vose, Julie M.
    Tabernero, Josep
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1763 - 1770
  • [10] Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
    Inaba, Kanako
    Oda, Katsutoshi
    Ikeda, Yuji
    Sone, Kenbun
    Miyasaka, Aid
    Kashiyama, Tomoko
    Fukuda, Tomohiko
    Uehara, Yuriko
    Arimoto, Takahide
    Kuramoto, Hiroyuki
    Wada-Hiraike, Osamu
    Kawana, Kei
    Yano, Tetsu
    Osuga, Yutaka
    Fujii, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 323 - 331
1234